TRCT
LEXX icon

Tower Research Capital (TRC)’s Lexaria Bioscience LEXX Stock Holding History

Tower Research Capital (TRC)’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$22 – 5078
2025
Q4 		$20 Sell
2
-239
-99% -$3.39K ﹤0.01% 5100
2025
Q3 		$3.45K Buy
241
+110
+84% +$1.6K ﹤0.01% 4501
2025
Q2 		$1.71K Buy
131
+44
+51% +$758 ﹤0.01% 4758
2025
Q1 		$2.22K Sell
87
-52
-37% -$1.32K ﹤0.01% 4576
2024
Q4 		$4.37K Buy
139
+49
+54% +$1.81K ﹤0.01% 4473
2024
Q3 		$4.1K Sell
90
-135
-60% -$6.44K ﹤0.01% 4673
2024
Q2 		$9.37K Buy
225
+45
+25% +$2.02K ﹤0.01% 4260
2024
Q1 		$9.81K Sell
180
-207
-53% -$7.91K ﹤0.01% 3787
2023
Q4 		$7.26K Sell
387
-168
-30% -$3.25K ﹤0.01% 4638
2023
Q3 		$8.33K Sell
555
-175
-24% -$2.4K ﹤0.01% 4362
2023
Q2 		$7.99K Buy
730
+457
+167% +$8.88K ﹤0.01% 4490
2023
Q1 		$11K Sell
273
-62
-19% -$2.65K ﹤0.01% 4232
2022
Q4 		$12K Buy
335
+93
+38% +$3.34K ﹤0.01% 3723
2022
Q3 		$9K Buy
+242
New +$10.3K ﹤0.01% 4665
2022
Q2 		– Sell
-204
Closed -$10K – 6330
2022
Q1 		$10K Buy
204
+124
+155% +$7.02K ﹤0.01% 4318
2021
Q4 		$5K Buy
+80
New +$6.83K ﹤0.01% 5163
2021
Q3 		– Sell
-17
Closed -$2K – 5979
2021
Q2 		$2K Buy
+17
New +$1.52K ﹤0.01% 5051

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Tower Research Capital (TRC)'s LEXX Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Lexaria Bioscience (LEXX) in Q1 2026, closing a stake of 2 shares — an estimated $22 sold.

Tower Research Capital (TRC) first reported a position in LEXX in Q2 2021 and held it in 17 quarters. The position peaked at $12K in Q4 2022. 25 funds tracked by Wall St. Rank hold LEXX as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Lexaria Bioscience position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2 Lexaria Bioscience shares in Q1 2026, an estimated $22.
  • Tower Research Capital (TRC) first reported a position in Lexaria Bioscience in Q2 2021 and held it in 17 quarters.
  • Tower Research Capital (TRC)'s Lexaria Bioscience position peaked at $12K in Q4 2022.
  • 25 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.